ReviewInternational journal of nanomedicine2025
Pathological Mechanisms of Radiation-Induced Lung Injury and Novel Nano-Drug Delivery Therapeutic Strategies.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Effects of Fractionated Low Dose Ionizing Radiation on Cellular Senescence in Mouse Lung Tissue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- A Huaxian Formula Nanoformulation Confers Protection Against Acute Radiation-Induced Lung Injury by Targeting Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model.Journal of radiation research · 2026Article
- Hydrogels for Healing Radiation-Injured Tissues and Organs.Gels (Basel, Switzerland) · 2026Review
- Breast cancer radiotherapy and the risk of lung injury: Advances and perspectives.Advances in radiotherapy & nuclear medicine · 2026Article
- Dasatinib and quercetin mitigate radiation-induced lung injury by eliminating senescent cells in a rat model.Frontiers in pharmacology · 2026Article
- The potential role of lily polysaccharide in mitigating radiation-induced pneumonitis via the gut-lung axis: a comprehensive review.Frontiers in pharmacology · 2026Review
- Molecular mechanisms and network interactions in radiation-induced lung injury.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced lung injury (RILI), encompassing early radiation pneumonitis (RP) and late radiation-induced lung fibrosis (RILF), remains a major dose-limiting complication of thoracic radiotherapy. The pathological processes involve oxidative stress, DNA damage, inflammatory cascades (notably IL-1, IL-6, TNF-α, and TGF-β), and fibrotic remodeling, yet current therapies-such as corticosteroids and antifibrotic agents-provide only partial relief and are often accompanied by significant side effects. Recent advances in nano-drug delivery systems (NDDS) offer new opportunities to overcome these limitations through targeted pulmonary delivery, stimuli-responsive release, and synergistic modulation of pathological pathways. Nanoformulations, including hyaluronic acid-based carriers, ROS-responsive microspheres, and inhalable nanomedicines, demonstrate enhanced pulmonary bioavailability, reduced systemic toxicity, and multi-mechanistic therapeutic potential. With continued refinement of intelligent nanocarriers and integration of advanced diagnostic tools, NDDS holds strong promise for translating preclinical advances into precise, individualized therapies for RILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.